Orally inhaled dihydroergotamine: Reviving and improving a classic

Future Neurology

Volumn 6, Issue 3, 2011, Pages 327-333

  Baron, Eric P ^a   Tepper, Stewart J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

cluster; DHE; dihydroergotamine; ergot; headache; Levadex; MAP0004; migraine; orally inhaled DHE; status migrainosus

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DIHYDROERGOTAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOTAMINE; LEVADEX; MAP 0004; NONSTEROID ANTIINFLAMMATORY AGENT; PERGOLIDE; PLACEBO; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANALGESIC ACTIVITY; ARTICLE; BRADYCARDIA; CLUSTER HEADACHE; COUGHING; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHORIA; EDEMA; HEADACHE; HEART MUSCLE FIBROSIS; HEART PALPITATION; HUMAN; LEG CRAMP; LIMB WEAKNESS; LIVER METABOLISM; LUNG DISEASE; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; MIGRAINE AURA; MUSCLE CRAMP; MYALGIA; NAUSEA; NONHUMAN; NOSE CONGESTION; PAIN PARAMETERS; PARESTHESIA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT MONITORING; PERICARDIAL DISEASE; PERITONEAL DISEASE; PLEURA DISEASE; PRIORITY JOURNAL; PRURITUS; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; SIDE EFFECT; TACHYCARDIA; TASTE AVERSION; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; VALVULAR HEART DISEASE; VASOCONSTRICTION; VOMITING;

EID: 79955655728     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/fnl.11.24     Document Type: Article

References (40)

1. Baron EP, Tepper SJ: Revisiting the role of ergots in the treatment of migraine and headache. Headache 50(8), 1353-1361 (2010). Provides the most recent historical review of ergots and dihydroergotamine (DHE).
2. Silberstein SD, McCrory DC: Ergotamine and dihydroergotamine: History, pharmacology, and efficacy. Headache 43(2), 144-166 (2003). (Pubitemid 36188447)
3. Stoll A, Hofmann A: Die alkaloide der ergotoxin-gruppe: Ergocristin, ergokryptin, ergocomine. Helv. Chir. Acta 25, 1570-1601 (1943).
4. Horton BT, Peters GA, Blumenthal LS: A new product in the treatment of migraine: A preliminary report. Mayo Clin. Proc. 20, 241-248 (1945).
5. Callaham M, Raskin N: A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache 26(4), 168-171 (1986). (Pubitemid 17199220)
6. Raskin NH: Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 36(7), 995-997 (1986).
7. Olesen J: The Headaches. (3rd Edition). Lippincott Williams & Wilkins, PA, USA (2006).
8. Tepper SJ, Millson D: Safety profile of the triptans. Expert Opin. Drug Saf. 2(2), 123-132 (2003).
9. Tepper SJ: Safety and rational use of the triptans. Med. Clin. North Am. 85(4), 959-970 (2001). (Pubitemid 32667301)
10. Bigal ME, Tepper SJ: Ergotamine and dihydroergotamine: A review. Curr. Pain Headache Rep. 7(1), 55-62 (2003). (Pubitemid 38915071)
11. Fisher M, Gosy EJ, Heary B, Shaw D: Dihydroergotamine nasal spray for relief of refractory headache: A retrospective chart review. Curr. Med. Res. Opin. 23(4), 751-755 (2007). (Pubitemid 46631478)
12. Cook RO, Shrewsbury SB, Ramadan NM: Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: Potential mechanism. Headache 49(10), 1423-1434 (2009). Discusses the reduced adverse event profiles of orally inhaled (INH) DHE compared with intravenous DHE.
13. Winner P, Ricalde O, Le Force B, Saper J, Margul B: A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch. Neurol. 53(2), 180-184 (1996). (Pubitemid 26055266)
14. Saper JR, Silberstein S, Dodick D, Rapoport A: DHE in the pharmacotherapy of migraine: Potential for a larger role. Headache 46(Suppl. 4), S212-S220 (2006). (Pubitemid 44656906)
15. Silberstein SD, Young WB, Hopkins MM, Gebeline-Myers C, Bradley KC: Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: An open-label pilot trial. Headache 47(6), 878-885 (2007). (Pubitemid 46944351)
16. Kori S, Tepper S, Boland S, Wang M, Hu B, Silberstein S: Evaluation of efficacy and safety of levadex (MAP0004) in reversing central sensitization and treating migraine in established allodynic patients. J. Headache Pain 11(Suppl. 1), 466 (2010).
17. Kori S, Tepper S, Mathew N et al.: Efficacy evaluation of levadex in treating resistant migraine including migraine with allodynia, disabling migraine and migraine treated late. J. Headache Pain. 11(Suppl. 1), 464 (2010).
18. Humbert H, Cabiac MD, Dubray C, Lavene D: Human pharmacokinetics of dihydroergotamine administered by nasal spray. Clin. Pharmacol. Ther. 60(3), 265-275 (1996). (Pubitemid 26354447)
19. Muller-Schweinitzer E: Pharmacological actions of the main metabolites of dihydroergotamine. Eur. J. Clin. Pharmacol. 26(6), 699-705 (1984). (Pubitemid 14074642)
20. Saper JR, Silberstein S: Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 46(Suppl. 4), S171-S181 (2006). (Pubitemid 44656902)
21. Winner P, Dalessio D, Mathew N et al.: Concomitant administration of antiemetics is not necessary with intramuscular dihydroergotamine. Am. J. Emerg. Med. 12(2), 138-141 (1994). (Pubitemid 24112539)
22. Shrewsbury SB, Kori SH, Miller SD, Pedinoff A, Weinstein S: Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics. Curr. Med. Res. Opin. 24(7), 1977-1985 (2008). Demonstrates INH DHE to be safe and effective in adult asthmatics.
23. Silberstein SD, Young WB: Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology. Neurology 45(3 Pt 1), 577-584 (1995).
24. Shrewsbury SB, Cook RO, Taylor G, Edwards C, Ramadan NM: Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (TEMPO) inhaler. Headache 48(3), 355-367 (2008). Provides Phase I trial data of the safety, pharmacokinetics and tolerability of INH DHE. (Pubitemid 351517766)
25. Aurora SK, Rozen TD, Kori SH, Shrewsbury SB: A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache 49(6), 826-837 (2009). Provides Phase II trial data in adult migraine patients.
26. Aurora SK, Silberstein SD, Kori SH et al.: MAP0004, orally inhaled DHE: A randomized, controlled study in the acute treatment of migraine. Headache 51(4), 507-517 (2011). Provides Phase III trial data and discusses the results of the FREEDOM-301 trial.
27. Malaquin F, Urban T, Ostinelli J, Ghedira H, Lacronique J: Pleural and retroperitoneal fibrosis from dihydroergotamine. N. Engl. J. Med. 321(25), 1760 (1989). (Pubitemid 20020567)
28. Roth BL: Drugs and valvular heart disease. N. Engl. J. Med. 356(1), 6-9 (2007).
29. Haro-Estarriol M, Sabater-Talaverano G, Rodriguez-Jerez F, Obrador-Lagares A, Genis-Batlle D, Sendra-Salillas S: Pleural effusion and pulmonary hypertension in a patient with parkinson disease treated with cabergoline. Arch. Bronconeumol. 45(2), 100-102 (2009).
30. Frans E, Dom R, Demedts M: Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline. Eur. Respir. J. 5(2), 263-265 (1992).
31. Frank W, Moritz R, Becke B, Pauli R: Low dose cabergoline induced interstitial pneumonitis. Eur. Respir. J. 14(4), 968-970 (1999). (Pubitemid 29519367)
32. Townsend M, MacIver DH: Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for parkinson's disease. Heart 90(8), E47 (2004).
33. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G: Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovasc. Ther. DOI: 10.1111/j.1755-5922.2010.00169.x (2011) (Epub ahead of print).
34. Lauritzen M: Pathophysiology of the migraine aura. The spreading depression theory. Brain 117(Pt 1), 199-210 (1994). (Pubitemid 24103394)
35. Klapper J, Mathew N, Nett R: Triptans in the treatment of basilar migraine and migraine with prolonged aura. Headache 41(10), 981-984 (2001). (Pubitemid 34008134)
36. Kaniecki RG: The lack of specificity of international headache society criteria in distinguishing basilar migraine from migraine with typical aura. Headache 43(5), 510 (2003).
37. Artto V, Nissila M, Wessman M, Palotie A, Farkkila M, Kallela M: Treatment of hemiplegic migraine with triptans. Eur. J. Neurol. 14(9), 1053-1056 (2007). (Pubitemid 47300782)
38. Kowacs PA, Piovesan EJ, Tatsui CE, Lange MC, Ribas LC, Werneck LC: Prolonged migraine aura without headache arrested by sumatriptan. A case report with further considerations. Cephalalgia 19(4), 241-242 (1999). (Pubitemid 29268497)
39. Davidoff RA: Migraine Manifestations, Pathogenesis, and Management. Oxford University Press, NY, USA (2002).
40. van der Kuy PH, Lohman JJ, Hooymans PM, Ter Berg JW, Merkus FW: Bioavailability of intranasal formulations of dihydroergotamine. Eur. J. Clin. Pharmacol. 55(9), 677-680 (1999).